The VVUS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the VVUS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The VVUS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View VVUS Detailed Price Forecast - CNN Money||View VVUS Detailed Summary - Google Finance|
|View VVUS Detailed Summary - Yahoo! Finance||View VVUS Stock Research & Analysis - Zacks.com|
|View VVUS Trends & Analysis - Trade-Ideas||View VVUS Major Holders - Barrons|
|View VVUS Call Transcripts - NASDAQ||View VVUS Breaking News & Analysis - Seeking Alpha|
|View VVUS Annual Report - CompanySpotlight.com||View VVUS OTC Short Report - OTCShortReport.com|
|View VVUS Fundamentals - TradeKing||View VVUS SEC Filings - Bar Chart|
|View Historical Prices for VVUS - The WSJ||View Performance/Total Return for VVUS - Morningstar|
|View the Analyst Estimates for VVUS - MarketWatch||View the Earnings History for VVUS - CNBC|
|View the VVUS Earnings - StockMarketWatch||View VVUS Buy or Sell Recommendations - MacroAxis|
|View the VVUS Bullish Patterns - American Bulls||View VVUS Short Pain Metrics - ShortPainBot.com|
|View VVUS Stock Mentions - StockTwits||View VVUS Stock Mentions - PennyStockTweets|
|View VVUS Stock Mentions - Twitter||View VVUS Investment Forum News - Investor Hub|
|View VVUS Stock Mentions - Yahoo! Message Board||View VVUS Stock Mentions - Seeking Alpha|
|View Insider Transactions for VVUS - SECform4.com||View Insider Transactions for VVUS - Insider Cow|
|View VVUS Major Holdings Summary - CNBC||View Insider Disclosure for VVUS - OTC Markets|
|View Insider Transactions for VVUS - Yahoo! Finance||View Institutional Holdings for VVUS - NASDAQ|
|View VVUS Stock Insight & Charts - FinViz.com||View VVUS Investment Charts - StockCharts.com|
|View VVUS Stock Overview & Charts - BarChart||View VVUS User Generated Charts - Trading View|
VIVUS to Host Fourth Quarter and Full Year Business Update and Financial Results Conference Call on Tuesday, February 26, 2019
Posted on Wednesday February 13, 2019
CAMPBELL, Calif., Feb. 13, 2019 -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter and.
3 Biotech Stocks That Pay Solid Dividends
Posted on Tuesday February 05, 2019
Although many biotech stocks have been hit hard at the start of 2019 while the general market has rallied, this underperformance in the biotechnology space has presented at least two key benefits for investors looking to invest in the area. First, and perhaps the most obvious, is that being able to enter biotech stocks at a cheaper price -- assuming the companies are not fundamentally broken -- is much better than going in while the stocks are overpriced or in "rally mode". Second, in situations like this, companies' dividend yields go up. What all of this means is that despite the seemingly grim picture for biotech, there are actually several solid biotech dividend stocks to invest in now. The struggle is sifting through all the names and finding which of them are the best dividend stocks to invest in. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 F-Rated Stocks That Could Break Your Portfolio But don't worry, I've done the hard work for you. Below are three of the best biotech dividend stocks to buy now. Source: Shutterstock ### AbbVie (ABBV) AbbVie (NYSE:ABBV) trades at a modest price-to-earnings ratio of 21X, while shares yield 5.45%. Although short-term investors might be concerned that ABBV shares have been on a downtrend since topping in May 2018 at $122, there is still plenty of longer-term potential in ABBV to be hyped about. Much of the downside ABBV experienced occurred after its latest earnings report. AbbVie reported fourth-quarter adjusted profits that grew a solid 28% over last year; at $1.90 a share, the company achieved its guidance for the quarter. But the stock gave up around $10 a share, falling from $88 to around $78, after the report. Investors fretted over the 15% drop in international Humira sales. Biosimilar competition in Europe, which makes up 75% of its international Humira business, was expected. However, generic competition for its flagship drug does not concern ABBV management. It's likely that they're banking on a slew of new product releases in 2019 to offset the aggressive discounting from competitors. In fact, AbbVie is funding five major products for launch indications this year. This should drive revenue higher and lead to double-digit earnings-per-share growth for the company. All of which makes it one of the notable biotech dividend stocks to buy. Source: Everjean via Flickr ### Allergan (AGN) Allergan plc (NYSE:AGN) ended its last rally in October 2018, with AGN shares finally bottoming by the end of last year at around $130. The stock fell again from $160 to a recent price of $144 after reporting Q4 results. Right now, AGN shares will pay you a modest 2.1% dividend. And if the stock rebounds, the total return will be higher. The botox specialist reported $4.08 billion in revenue, down 5.7% from last year. Non-GAAP income fell 15.4% to $1.45 billion. Encouragingly, sales of Botox rose 9.4%, while the Juvederm collection, Lo Loestrin and Vraylar all rose in the double digits. Although these products are a smaller part of total revenue, it is enough for management to forecast revenue of $15 billion - $15.3 billion this year. * 7 Stocks That Won Super Bowl Sunday With management forecasting lighter results for the year, why should investors buy AGN stock for the dividends? The firm has six late-stage clinical programs, plans of one to two new product launches annually and the company has strong margins. It made $5.64 billion in operating cash flow last year. This is more than the $976 million it needs for the dividend. Source: Shutterstock ### Sanofi (SNY) After settling at around $42 at the start of 2019, Sanofi (NASDAQ:SNY) rallied steadily to close at around $43.45 recently. Now, at its 50-day simple moving average, shares have a dividend yield of 4.28%. Sanofi's underperformance is unusual. Other than trading at a slightly higher valuation at a P/E of 22X, the company did not report any negative news. If anything, the collaborations that this biotech firm has with Regeneron Pharmaceuticals (NASDAQ:REGN) should bolster investor confidence. Regeneron's Dupixent is becoming a blockbuster hit for treating Atopic Dermatitis. Alongside its efforts with REGN, SNY is also supplying the active ingredient of avanafil to Vivus (NASDAQ:VVUS). Another promising aspect bolstering the case for SNY stock is that on Jan. 23, the Food and Drug Administration approved the use of Sanofi's Fluzone in young children. When it reports earnings on Feb. 7, the company should not bring up any negative surprises. It should be consistent like Q3's report where the company reported sales growing 6.3% (at constant exchange rates). Its Bioverativ acquisition should continue to contribute meaningfully to sales. Looking ahead, an EMA decision in the first half of this year for its oncology drug Libtayo, plus an FDA action date of Feb. 6 for Cablivi, which treats a rare blood disorder, should keep investor confidence high. As of this writing, Chris Lau held shares of ABBV. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 F-Rated Stocks That Could Break Your Portfolio * 5 Fintech Stocks to Buy As This Mega Trend Gains Steam * 10 Cold Weather Stocks to Heat Up Your Returns Compare Brokers The post 3 Biotech Stocks That Pay Solid Dividends appeared first on InvestorPlace.
VIVUS Announces Date of 2019 Annual Meeting
Posted on Monday February 04, 2019
Pursuant to Rule 14a‑8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), stockholders may present proper proposals for inclusion in the 2019 Proxy Statement and for consideration at the Company’s 2019 Annual Meeting. To be eligible for inclusion in the 2019 Proxy Statement, a proposal must be received by the Company no later than February 18, 2019 and must otherwise comply with Rule 14a‑8.
Today's Research Reports on Trending Tickers: Array BioPharma and VIVUS
Posted on Tuesday January 15, 2019
NEW YORK, NY / ACCESSWIRE / January 15, 2019 / Wall Street extended losses on Monday as concerns of a global economic slowdown were reignited on weaker-than-expected economic data from China. In December, ...